Brands & Strategies: UA/NSTEMI

Table of Contents

Table of Contents

Table of Exhibits

Executive Summary

Section 1: Disease Dynamics

• Background
• Patient Population
• Prevalence and Diagnosis
• Prescribers
• Treatment Dynamics
  • Existing Treatments
  • Emerging Treatments
• Reimbursement Issues
• Market Summary

Section 2: Competitive Analysis

• Overview of Competitive Landscape
  • Promotional Spending
  • Physician Perceptions of UA/NSTEMI Competitors

Schering-Plough

• Cardiovascular Product Portfolio
• Goals and Vision in Cardiology
• Current Positioning
• Market Strategy
• Future Positioning
• Integrilin
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Future Positioning
• SCH-530348
  • History
  • Competitive Analysis
  • Future Positioning

Sanofi-Aventis

• Cardiovascular Product Portfolio
• Goals and Vision in Cardiology
• Current Positioning
• Market Strategy
• Future Positioning
• Lovenox
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Future Positioning

Eli Lilly

• Cardiovascular Product Portfolio
• Goals and Vision in Cardiology
• Current Positioning
• Market Strategy
• Future Positioning
• ReoPro
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Future Positioning
• Prasugrel
  • History
  • Competitive Analysis
  • Future Positioning

The Medicines Company

• Cardiovascular Product Portfolio
• Goals and Vision in Cardiology
• Current Positioning
• Market Strategy
• Future Positioning
• Angiomax
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Future Positioning
• Cangrelor
  • History
  • Competitive Analysis
  • Future Positioning

Merck

• Cardiovascular Product Portfolio
• Goals and Vision in Cardiology
• Current Positioning
• Market Strategy
• Future Positioning
• Aggrastat
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Future Positioning

Bristol-Myers Squibb

• Cardiovascular Product Portfolio
• Goals and Vision in Cardiology
• Current Positioning
• Market Strategy
• Future Positioning
• Plavix
  • History
  • Current Positioning
  • Competitive Analysis
  • Key Brand Strategies
  • Future Positioning

Emerging Competitor: GlaxoSmithKline

• Cardiovascular Product Portfolio
• Goals and Vision in UA/NSTEMI
• Arixtra
  • History
  • Competitive Analysis
  • Future Positioning

Section 3: Market Forecast

• Market Overview
  • Drug Sales by Region
  • Drug Sales by Class
• Market Forecast
  • GpIIb/IIIa Inhibitor Market
  • Heparin Market
  • Hirudin Market
  • ADP Receptor Antagonist Market
  • FXa Inhibitors
  • Thrombin Inhibitors

Section 4: Appendix

• Acronyms and Initialisms
• Methodology
  • Epidemiological Forecast Methodology
  • Market Forecast Methodology
  • Competitive Analysis Methodology
  • Survey Methodology

Table of Exhibits

Executive Summary

• Exhibit ES-1: Key Parameters of the UA/NSTEMI Market
• Exhibit ES-2: UA/NSTEMI Market ($US), Major Markets, 2006-2011
• Exhibit ES-3: UA/NSTEMI Market Competitive Position, 2006 and 2011
• Exhibit ES-4: UA/NSTEMI Brand Sales ($US), by Brand, 2006 and 2011
• Exhibit ES-5: UA/NSTEMI Market Shares, by Brand, 2006 and 2011
• Exhibit ES-6: Physician Perceptions of UA/NSTEMI Market Competitors

Section 1: Disease Dynamics

• Exhibit 1-1: Platelet Activation Pathways
• Exhibit 1-2: Prevalent and Diagnosed UA/NSTEMI Cases, Major Markets
• Exhibit 1-3: UA/NSTEMI Rate of Events, by Country, 2006
• Exhibit 1-4: UA/NSTEMI Prevalence, by Indication, Major Markets, 2006
• Exhibit 1-5: UA/NSTEMI Cases, US
• Exhibit 1-6: UA/NSTEMI Cases, Europe
• Exhibit 1-7: UA/NSTEMI Cases, Europe, Continued
• Exhibit 1-8: UA/NSTEMI Cases, Japan
• Exhibit 1-9: Unmet Needs in UA/NSTEMI Treatment
• Exhibit 1-10: Physician Perceptions of Unmet Needs in UA/NSTEMI Treatment
• Exhibit 1-11: Impact of Information Sources in UA/NSTEMI
• Exhibit 1-12: Leading UA/NSTEMI Drugs, by Drug Class
• Exhibit 1-13: Emerging UA/NSTEMI Drugs, by Drug Class
• Exhibit 1-14: UA/NSTEMI Sales ($US), by Country, 2006
• Exhibit 1-15: UA/NSTEMI Sales ($US), by Drug Class, 2006
• Exhibit 1-16: Average UA/NSTEMI Patient Shares, by Brand, 2006
• Exhibit 1-17: UA/NSTEMI Brand Sales ($US), by Brand, as a Percent of Total, 2006

Section 2: Competitive Analysis

• Exhibit 2-1: UA/NSTEMI Market Competitive Position, 2006 and 2011
• Exhibit 2-2: UA/NSTEMI Market ($US), by Company, 2006-2011
• Exhibit 2-3: Promotional Spend for UA/NSTEMI Therapies, by Company, 2006
• Exhibit 2-4: Promotional Spending for UA/NSTEMI Therapies, by Brand, 2006
• Exhibit 2-5: Importance of Factors on Physician Perception of a Cardiovascular Company
• Exhibit 2-6: Physician Ranking of UA/NSTEMI Competitors as Overall Cardiovascular Companies
• Exhibit 2-7: Physician Ratings of Factors Influencing Perception of a UA/NSTEMI Company
• Exhibit 2-8: Physician Ranking of UA/NSTEMI Competitors
• Exhibit 2-9: Physician Ranked "Best" UA/NSTEMI Market Competitors
• Exhibit 2-10: Summary of Schering-Plough' s Cardiovascular Product Portfolio
• Exhibit 2-11: Physician Perceptions of Schering-Plough in UA/NSTEMI
• Exhibit 2-12: Timeline of Integrilin' s Development
• Exhibit 2-13: GpIIb/IIIa Physician Prescribing, by Patient Group
• Exhibit 2-14: Physician Perceptions of Integrilin
• Exhibit 2-15: Ongoing Clinical Trials for Integrilin
• Exhibit 2-16: Ongoing Clinical Trials for Integrilin, Continued
• Exhibit 2-17: Integrilin Market ($US), 2006-2011
• Exhibit 2-18: Integrilin Market ($US), by Country, 2006-2011
• Exhibit 2-19: Price to Treat per Day ($US), Integrilin, by Country, 2006
• Exhibit 2-20: SCH-530348 Market ($US), 2006-2011
• Exhibit 2-21: SCH-530348 Market ($US), by Country, 2006-2011
• Exhibit 2-22: Expected Price to Treat per Day ($US), SCH-530348, by Country
• Exhibit 2-23: Summary of Sanofi-Aventis' Cardiovascular Product Portfolio
• Exhibit 2-24: Physician Perceptions of Sanofi-Aventis in UA/NSTEMI
• Exhibit 2-25: Timeline of Lovenox' Development
• Exhibit 2-26: Physician Perceptions of Lovenox and UFH
• Exhibit 2-27: Physician' s Key Drivers of Choice for Lovenox versus UFH
• Exhibit 2-28: Clinical Trials for Lovenox versus UFH
• Exhibit 2-29: Additional Ongoing Clinical Trials for Lovenox
• Exhibit 2-30: Lovenox Market ($US), 2006-2011
• Exhibit 2-31: Lovenox Market ($US), by Country, 2006-2011
• Exhibit 2-32: Price to Treat per Day ($US), Lovenox, by Country, 2006
• Exhibit 2-33: Summary of Eli Lilly' s Cardiovascular Product Portfolio
• Exhibit 2-34: Physician Perceptions of Eli Lilly in UA/NSTEMI
• Exhibit 2-35: Timeline of ReoPro' s Development
• Exhibit 2-36: Physician Perceptions of ReoPro
• Exhibit 2-37: Ongoing Clinical Trials for ReoPro
• Exhibit 2-38: Ongoing Clinical Trials for ReoPro, Continued
• Exhibit 2-39: ReoPro Market ($US), 2006-2011
• Exhibit 2-40: ReoPro Market ($US), by Country, 2006-2011
• Exhibit 2-41: Price to Treat per Day ($US), ReoPro, by Country, 2006
• Exhibit 2-42: Physician Perceptions of Prasugrel' s Impact on ACS Treatment
• Exhibit 2-43: Prasugrel Market ($US), 2006-2011
• Exhibit 2-44: Prasugrel Market ($US), by Country, 2006-2011
• Exhibit 2-45: Expected Price to Treat per Day ($US), Prasugrel, by Country
• Exhibit 2-46: Summary of The Medicines Company' s Cardiovascular Product Portfolio
• Exhibit 2-47: Physician Perceptions of The Medicines Company in UA/NSTEMI
• Exhibit 2-48: Timeline of Angiomax' Development
• Exhibit 2-49: Physician Perceptions of Angiomax
• Exhibit 2-50: Ongoing Clinical Trials for Angiomax
• Exhibit 2-51: Angiomax Market ($US), 2006-2011
• Exhibit 2-52: Angiomax Market ($US), by Country, 2006-2011
• Exhibit 2-53: Price to Treat per Day ($US), Angiomax, by Country
• Exhibit 2-54: Cangrelor Market ($US), 2006-2011
• Exhibit 2-55: Expected Cangrelor Revenue ($US), by Country, 2006-2011
• Exhibit 2-56: Expected Price to Treat per Day ($US), Cangrelor, by Country
• Exhibit 2-57: Summary of Merck' s Cardiovascular Product Portfolio
• Exhibit 2-58: Physician Perceptions of Merck in UA/NSTEMI
• Exhibit 2-59: Timeline of Aggrastat' s Development
• Exhibit 2-60: Physician Perceptions of Aggrastat
• Exhibit 2-61: Ongoing Clinical Trials for Aggrastat
• Exhibit 2-62: Aggrastat Market ($US), 2006-2011
• Exhibit 2-63: Aggrastat Market ($US), by Country, 2006-2011
• Exhibit 2-64: Price to Treat per Day ($US), Aggrastat, by Country
• Exhibit 2-65: Summary of BMS' Cardiovascular Product Portfolio
• Exhibit 2-66: Physician Perceptions of BMS in UA/NSTEMI
• Exhibit 2-67: Timeline of Plavix' Development
• Exhibit 2-68: Physician Perceptions of Plavix
• Exhibit 2-69: Key Drivers of Choice for Plavix Use
• Exhibit 2-70: Ongoing Clinical Trials for Plavix
• Exhibit 2-71: Plavix Market ($US), 2006-2011
• Exhibit 2-72: Plavix Revenue ($US), by Country, 2006-2011
• Exhibit 2-73: Price to Treat per Day ($US), Plavix, by Country, 2006-2011
• Exhibit 2-74: Summary of GSK' s Cardiovascular Product Portfolio
• Exhibit 2-75: Physican Perceptions of Arixtra
• Exhibit 2-76: Arixtra Market ($US), 2006-2011
• Exhibit 2-77: Arixtra Market ($US), by Country, 2006-2011
• Exhibit 2-78: Expected Price to Treat per Day ($US), Arixtra, by Country

Section 3: Market Forecast

• Exhibit 3-1: UA/NSTEMI Market ($US), Major Markets, 2006-2011 (Tabular Format)
• Exhibit 3-2: UA/NSTEMI Market ($US), Major Markets, 2006-2011 (Graphical Format)
• Exhibit 3-3: Key Events , UA/NSTEMI Market, 2006-2011
• Exhibit 3-4: UA/NSTEMI Market ($US), by Country, 2006-2011
• Exhibit 3-5: UA/NSTEMI Market ($US), by Drug Class, 2006-2011
• Exhibit 3-6: UA/NSTEMI Market, by Drug Class, as a % of Total, 2006 and 2011
• Exhibit 3-7: GpIIb/IIIa Inhibitor Market ($US), by Drug, 2006-2011
• Exhibit 3-8: GpIIb/IIIa Inhibitor Market ($US), by Country, 2006-2011
• Exhibit 3-9: GpIIb/IIIa Inhibitor Market ($US), by Brand, 2006-2011
• Exhibit 3-10: Heparin Market ($US), by Drug, 2006-2011
• Exhibit 3-11: Heparin Market ($US), by Country, 2006-2011
• Exhibit 3-12: Heparin Market ($US), by Brand, 2006-2011
• Exhibit 3-13: Hirudin Market ($US), by Drug, 2006-2011
• Exhibit 3-14: Hirudin Market ($US), by Country, 2006-2011
• Exhibit 3-15: ADP Receptor Antagonist Market ($US), by Drug, 2006-2011
• Exhibit 3-16: ADP Receptor Antagonist Market ($US), by Country, 2006-2011
• Exhibit 3-17: ADP Receptor Antagonist Market ($US), by Brand, 2006-2011

Section 4: Appendix

• Exhibit 4-1: Adjusted Price of Lovenox, 2006-2011
• Exhibit 4-2: Adjusted Price of Angiomax, 2006-2011
• Exhibit 4-3: Adjusted Price of Arixtra, 2006-2011
• Exhibit 4-4: Surveyed Physicians' Years of Practice
• Exhibit 4-5: Surveyed Physicians' Patients per Month
• Exhibit 4-6: Surveyed Physicians' Geographic Distribution